According to Santé Publique France, in 2022, cancer represented the leading cause of mortality in France, accounting for 25.5% of deaths, despite a clear improvement in therapeutic care over the last decades. In addition to antitumor therapy, patient care includes nutritional and physical activity approaches aimed at maintaining the quality of life and well-being of patients, while also preventing the loss of skeletal muscle mass associated with cancer.

Devices designed by Aminogram offer a fast, simple, non-invasive, and precise method to evaluate health risks and measure the impact of interventions based on body composition data. In less than 10 seconds, the analysis allows for monitoring changes in body composition, particularly skeletal muscle mass, in order to optimize care and improve patients’ quality of life.